Literature DB >> 28328147

Effect of needle diameter on the viability of equine bone marrow derived mesenchymal stem cells.

Hayley M Lang1, Lauren V Schnabel1, Jennifer M Cassano1, Lisa A Fortier1.   

Abstract

OBJECTIVES: Mesenchymal stem cells (MSCs) are frequently delivered via needle injection for treatment of musculoskeletal injuries. The purpose of this study was to evaluate the effect of needle diameter on the viability of MSCs.
METHODS: Equine bone marrow-derived MSCs from 5 horses were suspended in PBS, and held at room temperature for 7 hours to mimic shipping conditions. Two replicate samples for each needle size (20, 22, 23, or 25-gauge [ga]) were aspirated into a 3 mL syringe and re-injected into the holding vial 3 times, to reproduce the resuspension of cells prior to injection in clinical cases. Cells were stained with fluorescein diacetate and propidium iodide to measure viability. Flow cytometry (FC) was performed to compare cell debris and intact cells between groups.
RESULTS: MSC viability was higher when cells were passed through a 20-ga rather than a 25-ga needle. Cell suspensions passed through a 20-ga needle contained a larger percentage of intact cells, compared to 25-ga samples. The percentage of debris present in cell suspensions tended to increase with decreasing needle diameter. Neither horse nor passage had a significant effect on viability.
CONCLUSIONS: Cell damage is more likely when MSCs are passed through 25-ga rather than 20-ga needles. CLINICAL RELEVANCE: Use of needles larger than 25-ga is recommended to maintain the viability of MSCs injected in horses.
© 2017 The American College of Veterinary Surgeons.

Entities:  

Mesh:

Year:  2017        PMID: 28328147      PMCID: PMC5493497          DOI: 10.1111/vsu.12639

Source DB:  PubMed          Journal:  Vet Surg        ISSN: 0161-3499            Impact factor:   1.495


  20 in total

Review 1.  Stem cells: classifications, controversies, and clinical applications.

Authors:  Lisa A Fortier
Journal:  Vet Surg       Date:  2005 Sep-Oct       Impact factor: 1.495

Review 2.  Regenerative medicine for tendinous and ligamentous injuries of sport horses.

Authors:  Lisa A Fortier; Roger K W Smith
Journal:  Vet Clin North Am Equine Pract       Date:  2008-04       Impact factor: 1.792

Review 3.  Clinical update on the use of mesenchymal stem cells in equine orthopaedics.

Authors:  D D Frisbie; R K W Smith
Journal:  Equine Vet J       Date:  2010-01       Impact factor: 2.888

4.  Phenotypic expression of equine articular chondrocytes grown in three-dimensional cultures supplemented with supraphysiologic concentrations of insulin-like growth factor-1.

Authors:  Lisa A Fortier; Alan J Nixon; George Lust
Journal:  Am J Vet Res       Date:  2002-02       Impact factor: 1.156

5.  Scintigraphic evaluation of intra-arterial and intravenous regional limb perfusion of allogeneic bone marrow-derived mesenchymal stem cells in the normal equine distal limb using (99m) Tc-HMPAO.

Authors:  A Sole; M Spriet; L D Galuppo; K A Padgett; D L Borjesson; E R Wisner; R J Brosnan; M A Vidal
Journal:  Equine Vet J       Date:  2011-12-30       Impact factor: 2.888

6.  The effect of intralesional injection of bone marrow derived mesenchymal stem cells and bone marrow supernatant on collagen fibril size in a surgical model of equine superficial digital flexor tendonitis.

Authors:  C J Caniglia; M C Schramme; R K Smith
Journal:  Equine Vet J       Date:  2011-12-11       Impact factor: 2.888

7.  Clinical outcome after intra-articular administration of bone marrow derived mesenchymal stem cells in 33 horses with stifle injury.

Authors:  Dora J Ferris; David D Frisbie; John D Kisiday; C Wayne McIlwraith; Brent A Hague; Michael D Major; Robert K Schneider; Chad J Zubrod; Christopher E Kawcak; Laurie R Goodrich
Journal:  Vet Surg       Date:  2014-01-16       Impact factor: 1.495

8.  Histological and immunohistochemical evaluation of autologous cultured bone marrow mesenchymal stem cells and bone marrow mononucleated cells in collagenase-induced tendinitis of equine superficial digital flexor tendon.

Authors:  Antonio Crovace; Luca Lacitignola; Giacomo Rossi; Edda Francioso
Journal:  Vet Med Int       Date:  2010-03-22

Review 9.  Therapeutic use of stem cells in horses: which type, how, and when?

Authors:  Lauren V Schnabel; Lisa A Fortier; C Wayne McIlwraith; Karl M Nobert
Journal:  Vet J       Date:  2013-06-15       Impact factor: 2.688

10.  Evaluation of adipose-derived stromal vascular fraction or bone marrow-derived mesenchymal stem cells for treatment of osteoarthritis.

Authors:  David D Frisbie; John D Kisiday; Chris E Kawcak; Natasha M Werpy; C Wayne McIlwraith
Journal:  J Orthop Res       Date:  2009-12       Impact factor: 3.494

View more
  5 in total

1.  Cell density, dimethylsulfoxide concentration and needle gauge affect hydrogel-induced bone marrow mesenchymal stromal cell viability.

Authors:  Xia Chen; Alexander G Foote; Susan L Thibeault
Journal:  Cytotherapy       Date:  2017-10-03       Impact factor: 5.414

2.  Intra-Articular Injection of 2 Different Dosages of Autologous and Allogeneic Bone Marrow- and Umbilical Cord-Derived Mesenchymal Stem Cells Triggers a Variable Inflammatory Response of the Fetlock Joint on 12 Sound Experimental Horses.

Authors:  Lélia Bertoni; Thomas Branly; Sandrine Jacquet; Mélanie Desancé; Loïc Desquilbet; Pascaline Rivory; Daniel-Jean Hartmann; Jean-Marie Denoix; Fabrice Audigié; Philippe Galéra; Magali Demoor
Journal:  Stem Cells Int       Date:  2019-05-02       Impact factor: 5.443

3.  Evaluation of Allogeneic Bone-Marrow-Derived and Umbilical Cord Blood-Derived Mesenchymal Stem Cells to Prevent the Development of Osteoarthritis in An Equine Model.

Authors:  Lélia Bertoni; Sandrine Jacquet-Guibon; Thomas Branly; Mélanie Desancé; Florence Legendre; Martine Melin; Pascaline Rivory; Daniel-Jean Hartmann; Amandine Schmutz; Jean-Marie Denoix; Magali Demoor; Fabrice Audigié; Philippe Galéra
Journal:  Int J Mol Sci       Date:  2021-03-02       Impact factor: 5.923

4.  Novel Techniques to Improve Precise Cell Injection.

Authors:  Walter Linzenbold; Andreas Fech; Manuela Hofmann; Wilhelm K Aicher; Markus D Enderle
Journal:  Int J Mol Sci       Date:  2021-06-14       Impact factor: 5.923

Review 5.  Cell-Based Therapies for Joint Disease in Veterinary Medicine: What We Have Learned and What We Need to Know.

Authors:  Sophie Helen Bogers
Journal:  Front Vet Sci       Date:  2018-04-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.